Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis - PubMed
4 hours ago
- #Metformin
- #Diabetes mellitus
- #Abdominal aortic aneurysm
- Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease with high rupture mortality.
- Diabetes mellitus (DM) shows an inverse association with AAA development, progression, and rupture.
- Metformin and other glucose-lowering therapies may modulate aortic wall remodeling.
- Systematic review includes observational studies, RCTs, and experimental research on DM and AAA.
- DM is consistently linked to slower AAA growth and reduced rupture risk in over 30 studies.
- Metformin is the most studied glucose-lowering therapy, showing potential to slow AAA progression.
- Newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists have limited evidence.
- Metformin's effects on AAA may involve vascular mechanisms beyond glucose control.
- Further research, including large RCTs, is needed to confirm these findings.